These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9316833)

  • 1. Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement.
    Garner HR; Burke TF; Lawhorn CD; Stoner JM; Wessinger WD
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1253-61. PubMed ID: 9316833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM; Leander JD; Reel JK; Hynes MD
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
    Butelman ER; Winger G; Zernig G; Woods JH
    J Pharmacol Exp Ther; 1995 Feb; 272(2):845-53. PubMed ID: 7853203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
    Picker MJ
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice.
    Narita M; Takahashi Y; Takamori K; Funada M; Suzuki T; Misawa M; Nagase H
    Jpn J Pharmacol; 1993 May; 62(1):15-24. PubMed ID: 8393497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.
    Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS
    Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement.
    Negus SS; Mello NK
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1132-40. PubMed ID: 10454487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
    Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
    Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey.
    Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):245-52. PubMed ID: 2164093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.